Renova Therapeutics selected to present at Cavendish Global Health Impact Forum at Biocom

June 14, 2016

San Diego, CA – Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum co-hosted with Biocom, June 20-23, 2016, in San Diego.

Cavendish Global Forums assist family offices and foundations in developing and implementing their individual pro-social impact investing, grant-giving and philanthropy programs within health and the life sciences. In accomplishing this, the Forums showcase presentations and panel discussions by leading family offices, foundations, research institutions and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year.

The theme of the upcoming Forum is Innovation, Philanthropy and Investing Inspired for Impact. “Working with our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” explains J. Michael Moffat, Cavendish co-founder and Chairman. “The quality and originality of Renova Therapeutics’ research and scientific insights in heart failure and type 2 diabetes positions them to make a major contribution to treat these debilitating chronic diseases.”

“Presenting at the Cavendish Global Forum is an honor and a testament to our gene therapy efforts in treating cardiovascular and metabolic diseases that affect millions of people worldwide,” said Jack W. Reich, Ph.D., CEO and co-founder of Renova Therapeutics. “We look forward to meeting with accomplished scientists, thought-leaders and philanthropists who echo our mission of restoring the health and renewing the lives of people around the world.”

The Cavendish Global community consists of more than 200 leading family offices and foundations from around the world with combined assets of over $225 billion. All participants share a passion for pro-social endeavors within health and the life sciences. The Forum is also an opportunity for family offices to champion and share information on projects and organizations about which they are passionate with other family offices from around the world.

About Renova Therapeutics

Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company’s lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company’s product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship-building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year. For more information, visit

Subscribe to receive company press releases and announcements